Israel’s Biond Biologics (see here previously) has begun multi-center trials of BND-35. It is already trialing BND-22. Both are immunotherapy treatments for solid tumors. https://nocamels.com/2024/06/novel-cancer-immunotherapy-drug-given-to-first-patient-in-trial/ https://www.biondbio.com/clinical-trials/ https://www.clinicaltrials.gov/study/NCT06274437?term=BND-35&rank=1 https://www.clinicaltrials.gov/study/NCT04717375?term=BND-22&rank=1

Researchers at Israel’s Bar-Ilan University are the first to analyze biopsies to discover how cancer cells prevent being destroyed by the immune system. As each patient is different, the results will help scientists develop personalized strategies for destroying tumors. https://www.biu.ac.il/en/article/580703 … Continue reading →

A team led by Weizmann scientists has discovered that the protein PSME4 is produced by cancer cells to stop the immune system from attacking the tumor. Reducing PSME4 levels should potentially render tumors more vulnerable to immunotherapy. https://www.jns.org/israeli-researchers-unmask-how-cancer-camouflages-itself/ https://wis-wander.weizmann.ac.il/life-sciences/dumpster-diving-cancer-tissue-uncovers-immune-evasion-mechanism https://www.nature.com/articles/s43018-023-00557-4

Scientists at Jerusalem’s Hadassah hospital and Bar-Ilan University have developed HBI0101- a CAR-T therapy for multiple myeloma and amyloidosis, benefiting over 90% of patients in trials. Los Angeles-based Immix BioPharma will commercialize HBI0101. https://www.timesofisrael.com/after-demonstrating-57-remission-rate-israeli-immunotherapy-licensed-by-us-firm/ https://haematologica.org/article/view/haematol.2022.281628

More details on the breakthrough technology of Israel’s Nectin (see here previously). Monoclonal antibodies, with toxins attached, are sent directly to the cancer cell to break its ability to immobilize the body’s immune system. Clinical trials are expected to start … Continue reading →

Scientists at Israel’s Bar-Ilan University and Hadassah-University Medical Center, have developed a treatment for multiple myeloma. The patient’s T-cells are combined with a chimeric antigen receptor (CAR) molecule. In Phase 1 human trials at Hadassah. https://www.jpost.com/health-science/groundbreaking-made-in-israel-treatment-may-offer-cure-for-blood-cancer-664422

There is a complex relationship between bacteria and cancer (reported here previously). Now, scientists at Israel’s Weizmann Institute have discovered that bacteria inside cancer cells can provoke an immune reaction against the tumor, which chemotherapy can further exploit. https://wis-wander.weizmann.ac.il/life-sciences/bacteria-may-aid-anti-cancer-immune-response https://www.nature.com/articles/s41586-021-03368-8

Israeli biotech Immunovative Therapies purifies and cultures healthy T-cells from an unmatched donor. The cells (called AlloStim) are injected into the cancer patient and after several treatments, boosts the recipient’s immune system to kill the tumors. Phase 2/3 trials in … Continue reading →

I have reported nearly 20 articles (see here) about Israeli scientists using immunotherapy to tackle cancer. Now Israel’s Cancer Research Fund and US Cancer Research Institute are partnering to decide which, of 160 Israeli research projects, could make the next … Continue reading →

I reported previously (many times) of Israeli scientists who are boosting the body’s immune system to fight cancer. Now Weizmann’s Dr Rony Dahan has developed a cancer immunotherapy compound that is 30 times more effective than existing treatments. http://www.weizmann.ac.il/WeizmannCompass/sections/new-scientists/making-immunotherapy-more-effective